SUPERIOR PERSISTENCE WHILE ON LABELED MAINTENANCE DOSE AMONG BIO-NAIVE PATIENTS WITH CROHN'S DISEASE INITIATED ON USTEKINUMAB COMPARED TO ADALIMUMAB

被引：0
|
作者：
Zhdanava, Maryia
Ding, Zhijie
Manceur, Ameur
Zhao, Ruizhi
Holiday, Christopher
Kachroo, Sumesh
Muser, Erik
Pilon, Dominic
机构：
来源：
GASTROENTEROLOGY | 2023年 / 164卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S47 / S47
页数：1
相关论文
共 50 条
  • [21] Ustekinumab in bio-naive and bio-failure Crohn's disease patients: Results from a "real-life" monocentric cohort
    Monin, L.
    Dubois, S.
    Reenaers, C.
    Van Kemseke, C.
    Latour, P.
    Van Daele, D.
    Vieujean, S.
    Seidel, L.
    Louis, E.
    DIGESTIVE AND LIVER DISEASE, 2021, 53 (01) : 72 - 78
  • [22] Healthcare resource utilization following ustekinumab initiation among bio-naive Canadian patients with moderately-to-severely active Crohn's disease
    Bessissow, Talat
    Narula, Neeraj
    Ma, Christopher
    In, Tracy S. H.
    Pone, Eneda
    Eberg, Maria
    Jairath, Vipul
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (10) : 1690 - 1697
  • [23] Leukocyte Adhesive Function as Potential Predictive Marker for Treatment Response to Vedolizumab Among Bio-naive Patients with Crohn's Disease
    Liu, J.
    Cheng, Q.
    Cao, Q.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : I1077 - I1078
  • [24] TREATMENT PERSISTENCE AND MAINTENANCE DOSING FOR USTEKINUMAB AND ADALIMUMAB AMONG PATIENTS WITH CROHN'S DISEASE WITH TWO-YEARS FOLLOW-UP IN THE SYMPHONY HEALTH DATABASE
    Muser, Erik
    Obando, Camilo
    Ding, Zhijie
    Slaton, Terra
    Kozma, Chris
    GASTROENTEROLOGY, 2020, 158 (06) : S959 - S959
  • [25] Adherence to and Persistence with Adalimumab Therapy among Swedish Patients with Crohn's Disease
    Liu, Yifei
    Soderberg, Joakim
    Chao, Jingdong
    PHARMACY, 2022, 10 (04)
  • [26] Better off NaiVE: Predictors of Adalimumab Dose Escalation in Patients With Crohn's Disease
    Moncrief, Karli
    Steinhart, A. Hillary
    Croitoru, Ken
    Newman, Alvin
    Nguyen, Geoffrey C.
    Xu, Wei
    Silverberg, Mark S.
    GASTROENTEROLOGY, 2012, 142 (05) : S359 - S359
  • [27] Real-world effectiveness and safety of ustekinumab in bio-naive patients with moderate-to-severe Crohn's disease: A Canadian multi-center study
    Bessissow, Talat
    Narula, Neeraj
    Ma, Christopher
    In, Tracy S. H.
    Eberg, Maria
    Karra, Kinda
    Jairath, Vipul
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (01) : 61 - 69
  • [28] THE COST-EFFECTIVENESS OF USTEKINUMAB COMPARED TO INFLIXIMAB AND ADALIMUMAB IN ADULT PATIENTS WITH MODERATE-SEVERE CROHN'S DISEASE (TNF NAIVE POPULATION)
    Aliyev, E. R.
    Hay, J. W.
    Hwang, C.
    VALUE IN HEALTH, 2018, 21 : S84 - S84
  • [29] Real-World Clinical Effectiveness and Safety of Vedolizumab and Ustekinumab in Bio-Naive Patients With Early Crohn's Disease: Results From the EVOLVE Expansion Study
    Christensen, Britt
    Scharl, Michael
    Bressler, Brian
    Khan, Zaeem
    Halchenko, Yuliya
    Kamble, Pravin
    Adsul, Shashi
    Farhat, Zeinab
    Ferrante, Marc
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S637 - S638
  • [30] Adalimumab maintenance therapy for patients with Crohn's Disease is cost effective compared with nonbiologic maintenance therapy
    Feagan, B.
    Loftus, E., Jr.
    Johnson, S.
    Wu, E.
    Yu, A.
    Chao, J.
    Mulani, P.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (12) : S33 - S33
12345